Meeting
2016 ASCO Annual Meeting
Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.
Authors
Robyn Saw
Melanoma Institute Australia and The University of Sydney, North Sydney, Australia
Robyn Saw , Alexander M. Menzies , Alexander Guminski , Omgo E Nieweg , Kerwin F. Shannon , Maria Gonzalez , Sydney Ch'ng , Richard Kefford , John F Thompson , Jonathan Stretch , Andrew J Spillane , Richard A Scolyer , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01972347
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9583)
DOI
10.1200/JCO.2016.34.15_suppl.9583
Abstract #
9583
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Preliminary results from the international neoadjuvant melanoma consortium (INMC).
First Author: Alexander M. Menzies
Poster
2022 ASCO Annual Meeting
Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.
First Author: Alexander M. Menzies
Poster
2015 ASCO Annual Meeting
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.
First Author: Jennifer Ann Wargo
Poster
2023 ASCO Annual Meeting
Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.
First Author: Tarin Hennegan